Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC boosted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 167.9% during the third quarter, HoldingsChannel reports. The fund owned 172,802 shares of the company’s stock after buying an additional 108,311 shares during the period. HighTower Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $3,491,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in TEVA. Metis Global Partners LLC raised its position in Teva Pharmaceutical Industries by 5.5% in the third quarter. Metis Global Partners LLC now owns 16,249 shares of the company’s stock valued at $328,000 after purchasing an additional 848 shares during the period. GFS Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $404,000. Assetmark Inc. raised its holdings in Teva Pharmaceutical Industries by 84.6% in the 3rd quarter. Assetmark Inc. now owns 37,054 shares of the company’s stock valued at $748,000 after buying an additional 16,979 shares during the period. Public Sector Pension Investment Board lifted its position in Teva Pharmaceutical Industries by 11.5% in the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after buying an additional 69,000 shares during the last quarter. Finally, Cibc World Market Inc. boosted its stake in Teva Pharmaceutical Industries by 5.3% during the third quarter. Cibc World Market Inc. now owns 72,663 shares of the company’s stock worth $1,468,000 after buying an additional 3,663 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TEVA shares. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Barclays lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $37.56.

Insider Activity

In other news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. The trade was a 68.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 422,060 shares of company stock worth $12,254,965. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $33.64 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The company has a market cap of $38.68 billion, a price-to-earnings ratio of 28.04, a price-to-earnings-growth ratio of 11.35 and a beta of 0.70. The stock’s 50-day moving average is $32.80 and its two-hundred day moving average is $25.50. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the previous year, the company posted $0.71 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.